IDEAYA Biosciences delays database lock for darovasertib trial to april

March 22, 2026 10:00 AM

IDEAYA Biosciences Inc. (NASDAQ: IDYA) announced updated guidance for its Phase 2/3 OptimUM-02 trial of darovasertib in first-line HLA-A2*-negative metastatic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found